Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. for failing to disclose that strong sales results were due to excess inventory accumulation rather than increased consumer demand, leading to a significant stock price decline after disappointing financial results were announced [7]. Group 1: Allegation Details - The lawsuit claims that BellRing's management did not inform investors that the strong sales figures were misleading, as they were primarily driven by customers building up inventory to avoid previous product shortages [7]. - Following the resolution of supply issues, customers began to destock, resulting in a reduction of new orders and revealing weakened demand due to competitive pressures [7]. Group 2: Financial Impact - On August 4, 2025, BellRing reported a disappointing fiscal Q3 2025 outlook, narrowing its net sales forecast to a range of $2.28 billion to $2.32 billion [7]. - The announcement led to a sharp decline in BellRing's stock price, dropping $17.46 per share, or nearly 33%, from $53.64 on August 4, 2025, to $36.18 on August 5, 2025 [7]. Group 3: Legal Process - Investors who purchased BellRing securities between November 19, 2024, and August 4, 2025, are encouraged to contact the law firm Bragar Eagel & Squire to discuss their legal rights and options [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 23, 2026 [7].

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant [1] - The FDA's complete response letter (CRL) indicated that while previous drug trials were acknowledged, additional evidence of effectiveness was required for a favorable benefit-risk assessment [2] - Following the FDA's announcement, Corcept's stock price experienced a significant drop of $31.42, representing a 44.76% decrease, opening at $38.78 per share [2] Company Performance - The stock price decline marks a new 52-week low for Corcept, reaching levels not seen since September 2024 [3] - The investigation by Levi & Korsinsky LLP aims to assist investors who may have suffered losses in Corcept's securities [3] Legal Context - Levi & Korsinsky LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex securities cases [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Richtech Robotics Inc. due to allegations of false and misleading statements regarding a supposed collaboration with Microsoft, which has led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Richtech to contact them directly to discuss legal options [1]. - The firm has set an April 3, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action against Richtech [2]. - The complaint alleges that Richtech and its executives violated federal securities laws by making false claims about their relationship with Microsoft [5]. Group 2: Stock Performance - On January 29, 2026, Richtech's stock fell by $1.06, or 20.87%, closing at $4.02, following a critical report questioning the company's Microsoft collaboration [6]. - The decline in stock price occurred amid broader market weakness, indicating potential vulnerabilities in investor confidence [6]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm has offices in New York, Pennsylvania, California, and Georgia, highlighting its extensive reach in the legal landscape [4].

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers of Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or the “Company”) that a federal securities class action has been filed on behalf of investors who purchased Beyond Meat shares between February 27, 2025 and November 11, 2025, inclusive (the “Class Period”). Investors have until March 24, 2026, to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Alle ...

Core Viewpoint - Inspire Medical Systems, Inc. is under investigation by Kahn Swick & Foti, LLC due to potential breaches of fiduciary duties and failure to disclose material information related to the launch of its Inspire V device [1][3]. Group 1: Company Issues - In August 2025, Inspire Medical Systems disclosed that the launch of its Inspire V device would face an "elongated timeframe" due to undisclosed issues, including incomplete training and onboarding at many centers, delayed software updates, and excess inventory leading to poor demand [2]. - As a result of these issues, the company significantly reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Group 2: Legal Actions - Following the disclosure of these issues, Inspire Medical Systems and certain executives were sued in a securities class action lawsuit for failing to disclose material information, which is still ongoing [3]. - KSF's investigation is focused on whether the company's officers and/or directors breached their fiduciary duties to shareholders or violated state or federal laws [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][5]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a company listed on NASDAQ under the ticker VTGN [2]. - The company is developing fasedienol, an investigational pherine candidate aimed at treating social anxiety disorder [5]. Group 2: Legal Investigation and Claims - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][7]. Group 3: Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock price drop of $3.50, or 80.27%, closing at $0.86 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Endeavor Group Holdings, Inc. for alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][5]. Group 1: Legal Investigation - The firm is looking into claims against Endeavor Group Holdings, Inc. and reminds investors of the March 18, 2026 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Endeavor and its executives made false and misleading statements and failed to disclose critical information in their filings with the U.S. Securities and Exchange Commission [5]. Group 2: Investor Rights - Investors who sold Endeavor Class A common stock between January 15, 2025, and March 24, 2025, are encouraged to discuss their legal rights with the firm [1]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [6]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for failing to disclose critical information regarding its business strategy and financial performance during the class period from June 4, 2024, to November 19, 2025 [2][5]. Allegation Details - The lawsuit alleges that Bath & Body Works did not disclose that its strategy of pursuing "adjacencies, collaborations and promotions" was ineffective in growing its customer base and did not deliver the expected growth in net sales [5]. - It is claimed that as the strategy faltered, the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [5]. - On November 20, 2025, the company reported disappointing third-quarter results, with a revenue decline of 1% year-over-year, missing the guidance of 1-3% growth, and a net income drop of 26% to $77 million [5]. Financial Performance - Bath & Body Works reduced its full-year guidance for net sales and cut expected earnings per diluted share from $3.28 to "at least $2.83" [5]. - Following the announcement of its underperformance and new business strategy, the stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [5]. Next Steps - Investors who purchased Bath & Body Works shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding their rights and potential claims [4].

Core Viewpoint - Regenxbio Inc. is under investigation for potential discrepancies between the information provided to investors and the actual safety developments in its gene therapy clinical programs, particularly following the FDA's clinical holds on its RGX-111 and RGX-121 programs due to safety concerns [1][2]. Group 1: Company Developments - On January 28, 2026, Regenxbio disclosed that the FDA placed clinical holds on its RGX-111 and RGX-121 programs after a tumor was identified in a trial participant, leading to a 30-35% decline in the company's share price [2]. - During the Q3 2025 earnings call on November 6, 2025, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections of clinical sites and the manufacturing facility with no observations, which may have created an asymmetric presentation of the company's regulatory standing [4]. - The Q3 2025 earnings call transcript did not mention the RGX-111 program for MPS I, despite it being a significant pipeline asset that would later face the same FDA clinical hold, raising concerns about the completeness of information provided to shareholders [5]. Group 2: Regulatory and Legal Context - SEC disclosure rules require public companies to provide material information necessary for informed investment decisions, and Rule 10b-5 prohibits material misstatements and omissions in securities transactions [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its clinical trial results [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Clinical Trial Results - Vistagen announced on December 17, 2025, that its Phase 3 PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder, failed to meet its primary efficacy endpoint, showing no statistically significant improvement compared to placebo [6]. - Following the announcement of the trial results, Vistagen's stock price dropped by $3.50, or 80.27%, closing at $0.86 on the same day [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].